Have you ever had a doctor roll his or her eyes or give you the brushoff after mentioning a health concern? If you’re like many women, it may not have been your imagination. As more and more research comes out … Read more
Corr BR, Moroney M, Sheeder J, et al
Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single-institution series with 132 patients to … Read more
The cover for issue 29 of Oncotarget features, “In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model,” by Lara, et al. which reported that adaptor proteins such as growth factor … Read more
These results suggest the need for future studies to examine scalable interventions to improve fatigue in women with gynecologic cancers.
By Hannah Slater
A 1-year longitudinal study published in Cancer suggested that almost half of women with gynecologic cancers had
Results of quality of life (QoL) assessments from the randomized, phase 3 ICON8 study evaluating once-weekly vs thrice-weekly administration of paclitaxel in combination with carboplatin as first-line chemotherapy in patients with epithelial ovarian cancer do … Read more
By Diana Swift
Population screening found to be cost-effective for higher income countries
Screening entire populations of women for mutations in breast and ovarian cancer susceptibility genes could prevent hundreds of thousands of cases in the U.S., and millions globally, … Read more
By Clayton Boldt, Ph.D
Advanced ovarian cancer most commonly metastasizes to the omentum, a layer of fatty tissue that wraps around and protects internal organs in the abdomen, but the reasons for this have not been well-understood. In a new … Read more
Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.
By Ryan McDonald
Despite limited data to support its use, the … Read more
A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%.
By Mark Leiser
A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results … Read more
A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.
Published today in the scientific … Read more
A recent data analysis found that most women diagnosed with ovarian cancer (92%) experienced abdominal and pelvic-related symptoms and visited a physician with this complaint anywhere from six to 70 months prior to diagnosis.
By Ryan McDonald
Data from a … Read more
According to new research published in Clinical and Translational Immunology, a new cancer vaccine is ready for human trials following its success in preclinical studies.
By Alana Hippensteele
The vaccine was recently developed by a research team based at The … Read more
High-grade serous epithelial ovarian cancer may be detected earlier in the course of the disease by testing for TP53 clonal variants in DNA from Pap tests.
By Leah Lawrence
High-grade serous epithelial ovarian cancer may be detected earlier in the … Read more
Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.
By Leah Lawrence
Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared … Read more
For years, The Clearity Foundation has emphasized the importance of tumor profiles/blueprints for informing decisions about treatment for ovarian cancer. Yet, genetic and tumor biomarker testing are not universally performed despite evidence that positive results in these tests could suggest … Read more
In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.
By Ian Demsky
A microRNA that is normally involved in immune cell differentiation helps to initiate
High-grade serous ovarian cancer (HGSOC) is characterized by a high level of intrinsic heterogeneity in the tumor-immune microenvironment that is modified by chemotherapy, according to findings published in Nature Genetics.
HGSOC, a common and … Read more
Inhibiting the JAK/STAT pathway could represent a potential treatment for high-grade serous ovarian cancer, according to a single-cell analysis.
Researchers led by the Broad Institute’s Aviv Regev used single-cell RNA sequencing (scRNA-seq) to analyze about 11,000 cells from ascites from … Read more
University of British Columbia (UBC) researchers have led an international team in developing a new test to better diagnose different types of ovarian cancer, a tool that could one day guide and improve treatment options for women diagnosed with the … Read more
By sharing your story with Clearity, you are helping us inspire the people who support us, as well as those that we support. Your stories are truly a gift to us. They help us to educate women who can benefit … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
